Recon – Page 20 – Selby Spine

Paxeon Reconstruction, a manufacturer of best-in-class orthopedic products including derivative and emerging products, announces that has received full clearance to introduce the Genius Knee to the marketplace.

In today’s orthopedic environment, it is important that companies not only provide quality products but also financially beneficial products. With that in mind, Paxeon Reconstruction has created a unique Value Solutions Program that has provided hospitals over $1.3m in savings through its first 12-months of clinical use. Physicians that have utilized Paxeon’s Total Hip Products have saved on average $1,315.00 per case.

Kyle Sineath, President of Paxeon Reconstruction said: “The addition of this total knee to our already proven hip implants is an exciting milestone for Paxeon. We look forward to adding the Genius Knee to our very successful Value Solutions Program to extend savings throughout the total joint continuum of care.”

About Paxeon Reconstruction

Paxeon Reconstruction builds best-in-class orthopaedic products, including derivative and emerging products. We collaborate with hospitals, health systems and physicians to create alignment and utilization of value-based solutions combined with efficiency models for today’s changing healthcare environment. Paxeon Reconstruction offer the world’s most comprehensive portfolio of orthopaedic products and services for joint reconstruction. Paxeon Reconstruction has a celebrated clinical history, and has evolved to meet the needs of the changing orthopaedics marketplace. The history that weaves the fabric of the Paxeon Reconstruction is one that is rich with innovation and demonstrates sustained leadership in an ever-changing landscape of patient and professional needs.

(New York, NY – July 14, 2017) – Mount Sinai has announced the opening of the Orthopaedic Center at Mount Sinai West. The new facility, located at 425 West 59th Street, is the first of its kind on Manhattan’s West Side, with state-of-the-art equipment and exam rooms to enhance patient experience and care.

The Orthopaedic Center at Mount Sinai West will be the Health System’s location for all orthopedic patient appointments on the West Side. The new facility offers a larger space to accommodate more patients and physicians specializing in all areas of orthopedics. Four new surgeons have joined the center’s 12 existing physicians to expand care and services in the areas of total joint replacement, sports medicine, spine, foot and ankle, shoulder, elbow and hand injuries. This facility gives patients new and direct on-site access to radiologists, rheumatologists, and pain management physicians for coordinated care.

Michael Bronson, MD, Chair, Department of Orthopaedics, Mount Sinai West; Chief, Joint Replacement Surgery, Mount Sinai West; and Associate Professor, Icahn School of Medicine at Mount Sinai, will direct the Orthopaedic Center at Mount Sinai West.

“We are extremely excited about the opening of our new facility, which will provide patients throughout the city and especially on the west side of Manhattan with state-of-the-art care, and give them access to orthopedic physicians in all sub-specialties,” said Dr. Bronson. “The Center will also provide immediate access to patients with acute orthopedic problems so these can be addressed in a timely manner. A larger facility means patients won’t have to wait weeks or months to see a world-renowned specialist.”

Additionally, the Orthopaedic Center at Mount Sinai West will serve as a major teaching site for medical students, residents, and fellows in all areas of orthopedics. This will add an extra level of expertise on the West Side, leading to increased medical research and breakthroughs in treatments to advance patient care.

“The Orthopaedic Center at Mount Sinai West represents Mount Sinai’s commitment to growth of the Department of Orthopaedics and signifies integration of care and dedication to patients on the West Side,” said Leesa Galatz, MD, System Chair, Orthopaedics, Mount Sinai Health System, and Mount Sinai Professor, Leni and Peter W. May Department of Orthopaedic Surgery, Icahn School of Medicine at Mount Sinai. “This is a center for excellence in orthopedics and patients will know that when they come here they will get exemplary care.”

About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

The System includes approximately 7,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is in the “Honor Roll” of best hospitals in America, ranked No. 15 nationally in the 2016-2017 “Best Hospitals” issue of U.S. News & World Report. The Mount Sinai Hospital is also ranked as one of the nation’s top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 10 nationally for Ophthalmology, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s, and Mount Sinai West are ranked regionally. Mount Sinai’s Kravis Children’s Hospital is ranked in seven out of ten pediatric specialties by U.S. News & World Report in “Best Children’s Hospitals.”

For more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.

Paxeon Reconstruction, a manufacturer of best-in-class orthopedic products including derivative and emerging products, announces successful 12-month clinical data utilizing its Total Hip Arthroplasty (THA) system. Paxeon has partnered with some of the top Orthopedic Surgeons in the country and the results of the follow-up has shown Paxeon products to be easy to use and effective.

In today’s orthopedic environment, companies must not only provide quality products but also financially beneficial products. With that in mind, Paxeon Reconstruction has created a unique Value Solutions Program that has provided hospitals over $1.3m in savings through its first 12-months of clinical use. Physicians utilizing Paxeon’s THA system save on average $1,315.00 per case.

Dr. Kevin Pugh (Pikeville, KY) says “I have been using Paxeon Reconstruction’s Origin hip system for the past 14 months. During that time, I have successfully completed nearly 200 Total Hip Arthroplasties with the Origin stem and Logical acetabular cup with no implant failures or repeat operations. These implants have provided excellent outcomes for my patients. The instrumentation is very user friendly and easy for my staff to learn. My hospital is pleased with the excellent service provided by Paxeon, as well as the tremendous savings that Paxeon has provided on the implants. As a company Paxeon has been very good to work with, as they have been very receptive to my individual needs as a surgeon. I am extremely happy with their products and am excited to watch them grow as a world leader in total joint reconstruction innovation.”

Dr. Chris Christensen (Lexington, KY) added “I am continually impressed with the ease of insertion of the origin stem. Broaching is much less physically demanding than other bone removal broaching systems. Patient comfort postop is excellent. At one year and 300 stems, the hip has performed essentially perfectly.”

Due largely to the success of their product portfolio, Paxeon Reconstruction is advancing through high quality implants and a unique value proposition that offers unparalleled advantages for both the surgeons and their hospitals. Kyle Sineath, President of Paxeon Reconstruction says “It’s proof that improved clinical outcomes are available at a savings to physicians and facilities. By providing showing clinical outcomes and significant savings, Paxeon is positioned as the true leader in the valued solutions market.”

About Paxeon Reconstruction

BILLERICA, Mass., July 11, 2017 (GLOBE NEWSWIRE) — ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that offers joint replacement implants customized to fit each patient’s unique anatomy, today announced that Dan Krupp has joined the Company as its Senior Vice President of U.S. Sales, effective July 3, 2017.

“The addition of Dan to our leadership team is another example of our commitment to developing additional expertise and support that will help us execute our commercial strategy,” said Mark Augusti, Chief Executive Officer and President of ConforMIS. “We are very excited to have Dan join us. His extensive experience in leading top-ranked sales organizations in startup, turnaround, volatile, and growth markets will be a tremendous asset for ConforMIS.”

Mr. Krupp has more than 20 years of sales and marketing experience in medical devices and total joint arthroplasty. From 2002-2014, he held positions of increasing responsibility at DePuy Synthes, developing and executing sales strategies and managing multiple new product launches. Most recently, he was Vice President, Sales and Marketing, at JACE Medical, where he successfully managed the development and execution of a range of corporate and product branding initiatives.

“I am very pleased to be joining the outstanding team at ConforMIS and to play a role in reshaping the future of arthroplasty with the company’s disruptive technology platform,” said Mr. Krupp. “I look forward to leading the U.S. sales force during what we believe will be a transformative period in orthopedics.”

About ConforMIS, Inc.

ConforMIS is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient’s unique anatomy. ConforMIS offers a broad line of customized knee implants and pre-sterilized, single-use instruments delivered in a single package to the hospital. In clinical studies, ConforMIS iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. ConforMIS owns or exclusively in-licenses approximately 450 issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/.

Cautionary Statement Regarding Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for ConforMIS, including statements about ConforMIS’s commercial strategy, future results, and orthopedic and arthroplasty markets, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our clinical studies and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent ConforMIS’s views as of the date hereof. ConforMIS anticipates that subsequent events and developments may cause ConforMIS’s views to change. However, while ConforMIS may elect to update these forward-looking statements at some point in the future, ConforMIS specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ConforMIS’s views as of any date subsequent to the date hereof.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/75f70387-ab76-48cd-bf98-27c3569e87df.

The photo is also available via AP PhotoExpress.

Investor Contact:
Oksana Bradley
ir@conformis.com
(781) 374-5598

Media Contact:
Bill Berry
Berry & Company Public Relations
Bberry@berrypr.com
(212) 253-8881

xslider-joint-replacement1.jpg.pagespeed.ic_.155VyO3lDs-1.jpg

Posted June 30, 2017 – Amy S. Wasterlain, MD; Ricardo J. Bello, MD, MPH; Jonathan Vigdorchik, MD; Ran Schwarzkopf, MD, MSc; William J. Long, MD, FRCSC

Abstract

Declining total joint arthroplasty reimbursement and rising implant prices have led many hospitals to restrict access to newer, more expensive total joint arthroplasty implants. The authors sought to understand arthroplasty surgeons’ perspectives on implants regarding innovation, product launch, costs, and cost-containment strategies including surgeon gain-sharing and patient cost-sharing. Members of the International Congress for Joint Reconstruction were surveyed regarding attitudes about implant technology and costs. Descriptive and univariate analyses were performed. A total of 126 surgeons responded from all 5 regions of the United States. Although 76.9% believed new products advance technology in orthopedics, most (66.7%) supported informing patients that new implants lack long-term clinical data and restricting new implants to a small number of investigators prior to widespread market launch. The survey revealed that 66.7% would forgo gain-sharing incentives in exchange for more freedom to choose implants. Further, 76.9% believed that patients should be allowed to pay incremental costs for “premium” implants. Surgeons who believed that premium products advance orthopedic technology were more willing to forgo gain-sharing (P=.040). Surgeons with higher surgical volume (P=.007), those who believed implant companies should be allowed to charge more for new technology (P<.001), and those who supported discussing costs with patients (P=.004) were more supportive of patient cost-sharing. Most arthroplasty surgeons believe technological innovation advances the field but support discussing the “unproven” nature of new implants with patients. Many surgeons support alternative payment models permitting surgeons and patients to retain implant selection autonomy. Most respondents prioritized patient beneficence and surgeon autonomy above personal financial gain. [Orthopedics. 201x; xx(x):xx–xx.]

During the past 20 years, increasing costs for total hip arthroplasty and total knee arthroplasty have outpaced increases in reimbursement.¹ Implant costs can comprise up to 50% of Medicare’s reimbursement for the entire procedure and hospitalization.^2,3 This rise in costs without a commensurate rise in reimbursement threatens hospitals’ financial stability and may therefore reduce patient access to care. In response, numerous cost-containment strategies have been proposed and implemented to reign in these costs. Value-based alternative payment models such as the Medicare bundled payment provide a fixed fee for all costs associated with a total joint arthroplasty, incentivizing all players to collaborate to provide better quality care at lower cost.⁴ Many hospitals have subsequently developed guidelines for implant use, restricting access to more expensive or newer implants.

Gain-sharing attempts to realign hospital and physician incentives by compensating surgeons for making cost effective decisions that yield savings for the hospital.⁴ Compensation may be in the form of bonus payments, additional personnel resources such as physician assistants, research funds, or another item of value to the physician or the department.⁵ Although surgeons may reap small rewards from gain-sharing, they may have less autonomy to choose the implants they believe are best for their patients.

READ THE REST HERE

WARSAW, Ind., July 11, 2017 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, announced that David C. Dvorak has stepped down as President and Chief Executive Officer and a member of the Board of Directors, effective today. To assist with the transition, Mr. Dvorak will serve in an advisory capacity to the Company for a period of time. The Board has appointed Daniel P. Florin, Senior Vice President and Chief Financial Officer, to serve in the additional role of Interim CEO and a member of the Board of Directors until a permanent successor has been named.

The Zimmer Biomet Board is retaining a leading executive search firm to identify and evaluate candidates for the permanent CEO role.

Mr. Dvorak said, “Serving alongside Zimmer Biomet’s dedicated employees over the past 16 years and leading the Company as CEO for ten of those years has been a privilege and a highlight of my professional career. Our collective efforts grew employment from approximately 3,000 in 2001 to 18,000 today and built a Fortune 500 company. I am particularly proud of what we have accomplished working together with surgeons and clinicians to help millions of patients globally improve their quality of life.”

Larry C. Glasscock, Chairman of the Board of Zimmer Biomet, commented, “During David’s ten-year tenure as CEO, Zimmer Biomet has transformed into a truly global leader in musculoskeletal healthcare. Through a combination of organic growth and strategic acquisitions, Zimmer Biomet’s revenue has doubled and the Company has established a leading portfolio of technologies, solutions and personalized services. With this strong platform in place, there is tremendous opportunity for Zimmer Biomet. On behalf of the Board, I thank David for his many important contributions to our Company and industry over the years and wish him much success in the future.”

Mr. Glasscock continued, “We are fortunate to have a leader of Dan’s caliber and experience to step into the CEO role on an interim basis while the Board conducts its search process. Dan’s knowledge of Zimmer Biomet and his achievements here and at other medical device companies make him an excellent choice to support the Company through this interim period. We appreciate his willingness to take on this expanded role.”

Mr. Florin said, “Zimmer Biomet has a talented and dedicated team and an unmatched portfolio. I am honored to assume the Interim CEO role and I look forward to working closely with the Board, senior leadership team and our sales force as we strive to support our customers and enhance stockholder value.”

About Dan Florin

Dan Florin was appointed Senior Vice President and Chief Financial Officer of Zimmer Biomet in June 2015 and has over 16 years of executive experience in the medical device industry. He previously served as Senior Vice President and Chief Financial Officer of Biomet from June 2007 to June 2015. Prior to joining Biomet, Mr. Florin served as Vice President and Corporate Controller of Boston Scientific Corporation from 2001 until 2007. Before being appointed Corporate Controller in 2001, Mr. Florin served in financial leadership positions within Boston Scientific Corporation and its various business units. Mr. Florin previously worked for C.R. Bard from October 1990 through June 1995, and Deloitte from September 1986 to October 1990. Mr. Florin holds a Bachelor’s degree in Business Administration with a concentration in Accounting from the University of Notre Dame and an Executive MBA from Boston University.

About Zimmer Biomet

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com, or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements that address expectations, plans or projections about the future, including statements about Zimmer Biomet’s management transition plans, growth prospects and business strategy, are forward-looking statements. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in its periodic reports. Accordingly, such forward-looking statements speak only as of the date made. Readers of this news release are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

ZBH-Corp

SOURCE Zimmer Biomet Holdings, Inc.

DRAPER, Utah, July 5, 2017 – Ortho Development^® Corporation (ODEV) is pleased to announce the signing of an agreement with China Pioneer Pharma Holdings Limited (CPP) as the exclusive distributor of ODEV’s Balanced Knee^® System in the People’s Republic of China.

China has recently surpassed Japan as the second largest market for orthopedic medical devices in the world. With an aging population and improvement in health insurance policies, the demand for total knee replacement procedures in China has been increasing rapidly. “Our strategic vision includes expanding distribution beyond the U.S. and Japanese markets into high-growth, emerging markets like China,” said Brent Bartholomew, President of ODEV. “We have been seeking the right distribution partner in China for quite some time, and are delighted to be working with an established, reputable partner like CPP.”

CPP is one of the largest comprehensive marketing, promotion and channel management service providers dedicated to importing pharmaceutical products and medical devices in China. Their portfolio includes ophthalmology, pain management, cardiovascular, respiratory, gastroenterology, immunology, orthopedics and other therapeutic areas, and a range of medical devices covering various medical specialties, including ophthalmology, odontology and wound care, etc. As of 31 December 2016, CPP sold products through its nationwide marketing, promotion and channel management service networks to approximately 30,000 hospitals and other medical institutions and over 108,000 pharmacies across all provinces, municipalities and autonomous regions in China.

Ortho Development’s Balanced Knee^® System (BKS) includes implants and instrumentation for primary and revision total knee replacement procedures. The design is based on proven technology with over 17 years of successful clinical results and more than 70,000 implanted worldwide. BKS implants are offered in a wide range of sizes and options to allow optimal anatomical fit for a variety of patients. The system has a patented locking mechanism specifically designed to minimize the micro-motion between the plastic tibial insert and the titanium tibial base plate implants. Simple and intuitive instrumentation facilitates reproducibility in the hands of every surgeon and aides in proper intraoperative balancing of the knee joint.

The medical device registration in China for the BKS has already been completed, and CPP intends to begin marketing the product immediately. Following the tender and bidding process with specific hospitals, CPP expects the first knee replacement procedures in China with BKS will occur in early 2018.

About Ortho Development Corporation

Ortho Development Corporation was founded in 1994 and is a privately held company located in Draper, Utah, U.S.A. The company is passionate about designing and manufacturing the best, clinically proven, high-performance orthopedic devices in the world. The primary product focus is total knee and hip joint replacement; and also includes trauma fracture repair, and spine treatment. Ortho Development products are distributed through a growing network of independent sales reps and distributors and are used by hundreds of surgeons at world-renowned orthopaedic hospitals and teaching universities, as well as in a widespread number of regional and community hospitals. The company’s majority shareholder is Japan Medical Dynamic Marketing, Inc. (Japan MDM), a publicly-traded, Japanese medical device distribution company.

7/6/2017

TAMPA, Fla. – Corin, a global manufacturer of orthopedic devices and high-tech solutions to improve surgical procedures, today announced that it will expand its US headquarters in Tampa. The company will up to 100 new high-wage jobs in marketing, operations, sales and other administrative roles and invest $500,000 in its new offices by 2022.

“We are fortunate to have such strong growth, which has enabled rapid expansion of our staff and facilities,” said Paul Berman, president of Corin USA. “Tampa has been and will continue to be a corridor of technological and healthcare innovation, which creates a strong base for talent and collaborative partnerships with other adjacent industries.”

Corin USA is a wholly-owned division of the 34-year-old British medical device company Corin Group LLC, located in Cirencester, UK. Corin USA was established 14 years ago in Tampa and is home to the company’s business activities in the US. Sales, marketing, clinical, regulatory, finance, and operations and logistics groups supporting the sales and marketing of Corin’s medical devices and technologies throughout the US are located at its regional office in Tampa.

Corin USA, which employs 30 individuals locally and over 100 across the US, moved this month from offices on West Cypress Street to 7,000 square feet of new space at 12750 Citrus Park Lane, Suite 120, Tampa, FL 33625.

As a leader in orthopedic innovation, Corin has pioneered a number of landmark developments since its inception in 1985. The company has improved the quality of life of hundreds of thousands of patients across the world through the introduction of its groundbreaking products.

In March 2017, Corin introduced its revolutionary Optimized Positioning System (OPS™) System at the American Academy of Orthopaedic Surgeons (AAOS) in San Diego. The technology may lead to one of the most significant changes to the way hip replacements are performed in more than 30 years.

The first-ever functional, patient-specific hip replacement procedures using OPS were performed in the US in November 2016, shortly after FDA clearance. More than 3,000 procedures have been done already in Europe and Australia, where the system was previously approved for use.

“No two patients are the same, so Corin is offering a patient-specific solution that gives the surgeon the information and tools necessary to enable an optimal hip replacement procedure based on each individual patient’s unique anatomy,” said Berman. “Feedback from surgeons who have used OPS has been excellent and interest in the system from the orthopedic community is very high.”

The Tampa Hillsborough Economic Development Corporation assisted Corin USA with its real estate property search as well as connections to workforce training programs and expedited permitting services.

“Hillsborough County’s life sciences sector is booming,” said Dr. Ken Atwater, chairman of the Tampa Hillsborough Economic Development Corporation and president of Hillsborough Community College. “The success that companies like Corin are enjoying is elevating our global reputation as an attractive location for others in this industry. Tampa offers Corin a highly skilled talent pool, close proximity to an exceptional international airport, and a business climate that supports their growth. We are proud to partner with Corin as they expand and thank them for bringing more great jobs to our community.”

Individuals interested in available jobs may refer to the company’s career website, here.

About Corin Group

Corin is a European orthopedic manufacturer based in the United Kingdom that markets its products throughout the world. Corin is committed to improving patient satisfaction with personalized technologies that optimize our clinically proven joint replacements; delivering a personal approach to our customers, combining the spirit of our local companies with the strength of our global, integrated organization; and empowering and rewarding our global talented teams to deliver excellence to our customers.

For further information about Corin, please visit www.coringroup.com.

About the Tampa Hillsborough Economic Development Corporation

The Tampa Hillsborough Economic Development Corporation is the lead designated economic development agency for Hillsborough County and the cities of Tampa, Plant City, and Temple Terrace. Established in 2009 as a partnership between the public sector and private corporate investors, the EDC works to develop and sustain a thriving local economy through the attraction, retention and expansion of high wage jobs and capital investment within targeted industry sectors.

Jody Stallings, Industrial Creations – 06.28.17

3D printing is becoming an important tool in nearly every industry today, but one area where it is really making an impact is in the medical field.

Doctors and surgeons can use 3D printed organ or bone models to explain to patients or students the details of a surgery or to practice the surgery itself. Other surgeons are actually designing their own prototypes of new surgical tools or bone replacement options.

The challenge, historically, is that 3D printing can be expensive and difficult to complete.

As a mechanical engineer, I began my career in automation design and robotics, but moved into the medical industry in 1990 when I was hired by an orthopedic knee replacement company. They asked me to utilize my experience to automate the process for finishing knee implants. It was a three-year project and the result was a new process that produced a knee implant in minutes instead of hours.

During that process, I saw the opportunity that surgeons have to develop new techniques and tools to enhance surgical procedures, but they lacked the resources to turn their ideas into a reality. Now, in my spare time I work with the doctors and surgeons to brainstorm a design based on their idea and 3D print it so that they can pitch to companies for production.

So, how does it all work?

An orthopedic surgeon comes up with an idea and it is then modeled using computer-aided design (CAD) software. The design is then printed using a desktop ABS 3D printer to fabricate the first conceptual models and get the surgeon to a point where they are happy with the design and are confident the part will be functional.

Up to this point, it’s fairly easy to manage time and expenses. However, when it comes time for a real functional prototype, that means working with metal and that’s when the costs start to increase. As the surgeons are often doing this on their own time and paying for it from their own pocket, it’s important that costs are managed.

READ THE REST HERE

knee_computer-assisted-surgery_exactechgps-link-display-stylus-1.png

June 29, 2017

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced the introduction of ExactechGPS® TKA PLUS, a new software application that provides orthopaedic surgeons simplified, real-time intraoperative computer guidance during total knee arthroplasty (TKA). The new application expands the ExactechGPS portfolio and complements the company’s new Truliant® Knee System which is also making its clinical debut this quarter.

Derek Amanatullah, MD, PhD, performed the first surgery using ExactechGPS TKA PLUS at Stanford University Medical Center. “I was delighted to experience how seamlessly the system integrated into my surgical workflow,” he reported. “ExactechGPS TKA PLUS allowed me to use simple guidance to achieve precision and accuracy in my cuts, which made the knee replacement case run smoothly. I believe this system is exactly what surgeons need to help them achieve more reproducible outcomes.”

ExactechGPS is a computer technology system for guided, personalized joint replacement surgery. The new TKA PLUS software application provides surgeons a simple tool to plan, guide and verify key steps of a knee replacement procedure and easily check the patient’s implant alignment. This new application expands the ExactechGPS knee software portfolio, which also includes comprehensive applications for both primary and revision knee surgery.

“The launch of TKA PLUS reiterates Exactech’s commitment to delivering a fully comprehensive knee system to the marketplace,” said Joseph Pizzurro, vice president of Knee Marketing at Exactech. “The Truliant system of new implants and instruments, combined with our ExactechGPS technology, offers orthopaedic surgeons versatility in managing total knee arthroplasty cases from primary through revision. We are encouraged by the positive responses we have received and look forward to continued momentum behind our new knee system.”

ExactechGPS has been used in more than 8,500 total knee cases in 12 countries across the globe. ExactechGPS TKA PLUS is available in pilot launch, with full availability expected in 2018.

About ExactechGPS

ExactechGPS combines surgeon expertise with an advanced computer system to perform the patient’s surgery with a goal of improved accuracy and precision. Personalized for a patient’s unique bone structure and anatomy, ExactechGPS is designed to allow surgeons to decide where to remove bone and place the implant in the optimal position. Exactech first introduced ExactechGPS to surgeons in the United States for total knee arthroplasty, and has since broadened its reach to the shoulder segment. The technology has steadily gained market acceptance and worldwide reach.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.

A current investment profile on Exactech (Nasdaq: EXAC) is available online at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

Contacts

Exactech
Investor contacts
Jody Phillips, 352-377-1140
Executive Vice President of Finance & Chief Financial Officer
or
Hawk Associates
Julie Marshall or Frank Hawkins, 305-451-1888
EXAC@hawkassociates.com
or
Exactech
Media contacts
Priscilla Bennett, 352-377-1140
Vice President, Corporate & Marketing Communication

Newer Posts

Older Posts

Search

3 days / 6 sessions
Current Issues in Spine

Paxeon Reconstruction Adds the Genius Knee to its Disruptive Savings Model After Receiving FDA Clearance

Mount Sinai Opens World-Class Orthopaedic Center on Manhattan’s West Side

Paxeon Reconstruction Announces Successful 12-Month Clinical Follow Up and A Unique Value Solutions Program That Has Produced Over $1.3m in Savings

ConforMIS Names Dan Krupp Senior Vice President U.S. Sales

Surgeons’ Perspectives on Premium Implants in Total Joint Arthroplasty

Abstract

Zimmer Biomet Announces Leadership Transition

Ortho Development Corporation signs exclusive distribution agreement with China Pioneer Pharma Holdings Limited

Corin USA expands headquarters in Hillsborough County, creating 100 new jobs

3D Printing Orthopedic Surgeons’ Invention Ideas

Exactech Introduces New Computer-Assisted Software Application for Simplified Guidance in Total Knee Replacement

Contacts

STAR Ankle Joint Replacements Last Long Term and Provide Relief for Patients

Medacta USA’s Spine Division Begins 2017 with Key Appointment, Significant Growth

Spinal Stabilization Technologies Announces Start of LOPAIN 2 Clinical Trial in South America for Lumbar Degenerative Disc Disease

$250K Pediatric Device Competition Now Accepting Proposals

First Single-Use Rigid Endoscope to be Demonstrated at AAOS